EYPT
Price
$8.26
Change
+$0.06 (+0.73%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
567.7M
54 days until earnings call
OCUL
Price
$8.46
Change
+$0.08 (+0.95%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.35B
67 days until earnings call
Interact to see
Advertisement

EYPT vs OCUL

Header iconEYPT vs OCUL Comparison
Open Charts EYPT vs OCULBanner chart's image
EyePoint Pharmaceuticals
Price$8.26
Change+$0.06 (+0.73%)
Volume$7.04K
Capitalization567.7M
Ocular Therapeutix
Price$8.46
Change+$0.08 (+0.95%)
Volume$32.82K
Capitalization1.35B
EYPT vs OCUL Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. OCUL commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (EYPT: $8.25 vs. OCUL: $8.46)
Brand notoriety: EYPT and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 59% vs. OCUL: 109%
Market capitalization -- EYPT: $567.7M vs. OCUL: $1.35B
EYPT [@Biotechnology] is valued at $567.7M. OCUL’s [@Biotechnology] market capitalization is $1.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, EYPT is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 6 TA indicator(s) are bullish while OCUL’s TA Score has 6 bullish TA indicator(s).

  • EYPT’s TA Score: 6 bullish, 4 bearish.
  • OCUL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both EYPT and OCUL are a good buy in the short-term.

Price Growth

EYPT (@Biotechnology) experienced а +14.42% price change this week, while OCUL (@Biotechnology) price change was +3.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

EYPT is expected to report earnings on Jul 30, 2025.

OCUL is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.35B) has a higher market cap than EYPT($568M). EYPT YTD gains are higher at: 10.738 vs. OCUL (-1.874). EYPT has higher annual earnings (EBITDA): -144.55M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. EYPT (318M). EYPT has less debt than OCUL: EYPT (24.1M) vs OCUL (76.2M). OCUL has higher revenues than EYPT: OCUL (59.6M) vs EYPT (56M).
EYPTOCULEYPT / OCUL
Capitalization568M1.35B42%
EBITDA-144.55M-176.35M82%
Gain YTD10.738-1.874-573%
P/E RatioN/AN/A-
Revenue56M59.6M94%
Total Cash318M350M91%
Total Debt24.1M76.2M32%
FUNDAMENTALS RATINGS
EYPT vs OCUL: Fundamental Ratings
EYPT
OCUL
OUTLOOK RATING
1..100
2313
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
4648
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (52) in the Pharmaceuticals Other industry is in the same range as EYPT (59) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

OCUL's Profit vs Risk Rating (86) in the Pharmaceuticals Other industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

OCUL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as EYPT (94) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as OCUL (48) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew similarly to OCUL’s over the last 12 months.

EYPT's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that EYPT’s stock grew significantly faster than OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 15 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYAWX106.16N/A
N/A
Rydex S&P 500 Pure Growth H
PQIAX39.68N/A
N/A
Principal Equity Income A
IYPCX19.58N/A
N/A
Macquarie Systematic Em Mkts Eq R
RDWHX11.91N/A
N/A
American Funds Dvlpg Wld Gr&Inc R5E
FTZIX51.94N/A
N/A
FullerThaler Behavrl Uncnstd Eq

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+0.60%
EYPT - OCUL
59%
Loosely correlated
+0.99%
DNLI - OCUL
50%
Loosely correlated
+3.52%
NRIX - OCUL
48%
Loosely correlated
+0.66%
ERAS - OCUL
48%
Loosely correlated
+5.88%
RVMD - OCUL
48%
Loosely correlated
-0.49%
More